



THE SECRETARY OF HEALTH AND HUMAN SERVICES
WASHINGTON, D.C. 20201

July 28, 2026

The Honorable Elizabeth Warren
United States Senate
Washington, DC 20510

Dear Senator Warren:

Thank you for your letter regarding the cost of prescription drugs for American patients. I appreciate your feedback on this issue.

The Administration is committed to reducing prescription drug costs for Americans. For decades, Americans have paid the highest prices in the world for brand-name prescription drugs. Meanwhile, manufacturers routinely offer significantly lower prices for the same medicines in peer nations such as Germany, the United Kingdom, France, and Canada. These disparities persist even when the products are identical and produced by the same companies.

TrumpRx increases access to drugs at discounted prices while improving drug price transparency. It is a central platform that aggregates prescription drug pricing from manufacturers that have agreed to provide American patients with prices negotiated under the Most Favored Nation (MFN) principle. The MFN principle holds that the United States should receive pricing terms that are at least as favorable as those offered to any comparable developed country. If a pharmaceutical manufacturer sells a drug at a lower net price abroad, American patients should have access to that same price.

TrumpRx works outside of traditional insurance coverage, allowing both insured and uninsured patients to directly access lower prices for their medications through two pathways. For some drugs, patients can generate a coupon card and purchase their prescription at participating pharmacies at a discounted price using the coupon card. For other drugs, patients must purchase their prescriptions directly through manufacturers' websites to get the discounted prices. This direct-to-consumer model offers Americans a simpler way to compare and check for the best prices for their prescriptions and ultimately access lower-cost prescription drugs.

TrumpRx does not sell drugs or fill prescriptions. TrumpRx also does not require patients to create an account or register to access the discounted prices. As a result, it does not store any patient, health, or prescription information.

In February 2026, TrumpRx launched with more than 40 brand drugs from the first five manufacturers to sign MFN agreements. As of May 18, 2026, TrumpRx expanded to include brand drugs from 12 additional manufacturers and more than 600 generic medications, listed

separately from the discounts on high-cost branded medications negotiated earlier this year.¹ More drugs will be added as new agreements are finalized. This expansion to include generic drugs advances the Administration's goal of making the drug purchasing process more transparent, competitive, and accessible for American patients.

Thank you again for your letter and for taking the time to share your views. HHS is committed to ensuring all Americans have access to lower prescription drug prices. If you have further thoughts or questions, please have your staff contact the Office of the Assistant Secretary for Legislation at (202) 690-7627.

Sincerely,

Robert F. Kennedy, Jr.

¹ <https://www.whitehouse.gov/fact-sheets/2026/05/fact-sheet-president-donald-j-trump-announces-expansion-of-trumprx-gov-to-bring-americans-transparency-and-choice-on-everyday-medicines/>